Mohammadi, MahmoudIJzerman, Nikki SHohenberger, PeterRutkowski, PiotrJones, Robin LMartin-Broto, JavierGronchi, AlessandroSchöffski, PatrickVassos, NikolaosFarag, SheimaBaia, MarcoOosten, Astrid WSteeghs, NeeltjeDesar, Ingrid M EReyners, An K Lvan Sandick, J WBastiaannet, EstherGelderblom, HansSchrage, Yvonne2025-01-072025-01-072021-03-31https://hdl.handle.net/10668/27243Oesophageal gastrointestinal stromal tumours (GISTs) account for ≤1% of all GISTs. Consequently, evidence to guide clinical decision-making is limited. Clinicopathological features and outcomes in patients with primary oesophageal GIST from seven European countries were collected retrospectively. Eighty-three patients were identified, and median follow up was 55.0 months. At diagnosis, 59.0% had localized disease, 25.3% locally advanced and 13.3% synchronous metastasis. A biopsy (Fine Needle aspiration n = 29, histological biopsy n = 31) was performed in 60 (72.3%) patients. The mitotic count was low (5/5hpf) mitotic count were associated with worse disease free survival. Based on the current study, enucleation can be recommended for oesophageal GIST smaller than 4 cm, while oesophagectomy should be preserved for larger tumours. Patients with larger tumours (>4 cm) and/or high mitotic count should be treated with adjuvant therapy.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Gastrointestinal stromal tumoursOesophagusSurgerySurvivalTreatment outcomeAgedAnastomotic LeakAntineoplastic AgentsBiopsy, Fine-NeedleChemotherapy, AdjuvantDisease-Free SurvivalEsophageal NeoplasmsEsophagectomyEsophagoscopyEuropeFemaleGastrointestinal Stromal TumorsHumansImatinib MesylateMaleMargins of ExcisionMiddle AgedMitotic IndexNeoadjuvant TherapyNeoplasm MetastasisPostoperative ComplicationsProgression-Free SurvivalPlastic Surgery ProceduresRetrospective StudiesTreatment OutcomeTumor Burdenresearch article33895019open access10.1016/j.ejso.2021.03.2341532-2157http://www.ejso.com/article/S0748798321003759/pdf